Get the Stockscreener App
1.25
3.47%
-0.045
After Hours:
1.27
0.02
+1.60%
Ernexa Therapeutics Inc stock is traded at $1.25, with a volume of 39,608.
It is down -3.47% in the last 24 hours and down -3.10% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$1.295
Open:
$1.32
24h Volume:
39,608
Relative Volume:
0.46
Market Cap:
$9.59M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.1504
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
-8.09%
1M Performance:
-3.10%
6M Performance:
-56.42%
1Y Performance:
-91.75%
1-Day Range:
$1.25
$1.32
1-Week Range:
$1.25
$1.40
52-Week Range:
$1.09
$18.75
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
1.25 | 9.93M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
What the charts say about Ernexa Therapeutics Inc. todayMarket Volume Report & Capital Efficient Trading Techniques - newser.com
Should I hold or sell Ernexa Therapeutics Inc. stock in 2025Earnings Growth Report & Verified Technical Signals - newser.com
Smart tools for monitoring Ernexa Therapeutics Inc.’s price action2025 Year in Review & Daily Momentum Trading Reports - newser.com
Why Ernexa Therapeutics Inc. stock could rally in 2025July 2025 Momentum & Weekly Breakout Stock Alerts - newser.com
Order flow analysis tools used on Ernexa Therapeutics Inc.2025 Volatility Report & Real-Time Chart Pattern Alerts - newser.com
Ernexa Therapeutics’ (ERNA) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
Historical volatility pattern of Ernexa Therapeutics Inc. visualizedJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
How moving averages guide Ernexa Therapeutics Inc. tradingWatch List & Long Hold Capital Preservation Plans - newser.com
Can Ernexa Therapeutics Inc. stock sustain market leadershipJuly 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
Custom strategy builders for tracking Ernexa Therapeutics Inc.Portfolio Profit Report & Smart Allocation Stock Tips - newser.com
Ernexa Therapeutics to Deliver Company Presentation At the Annual Cell & Gene Meeting on the Mesa - MarketScreener
Ernexa Therapeutics to Present at Cell & Gene Meeting on the Mesa, Highlighting Advances in iMSC Therapies for Cancer and Autoimmune Disease - Quiver Quantitative
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa - GlobeNewswire
Leading Cancer Cell Therapy: Ernexa Therapeutics to Showcase iMSC Platform at Major Industry Conference - Stock Titan
Ernexa Therapeutics: Interview With President & CEO Sanjeev Luther About The Innovative Cell Therapy Company - Pulse 2.0
Ernexa Therapeutics CEO Sanjeev Luther to Speak at 5th Annual iPSC Drug Development Summit - Quiver Quantitative
Ernexa Therapeutics President & CEO Sanjeev Luther to - GlobeNewswire
Cancer & Autoimmune Cell Therapy Pioneer: Ernexa CEO to Present iMSC Breakthroughs at iPSC Summit - Stock Titan
Ernexa Therapeutics Inc Stock Analysis and ForecastResistance Breakout Alerts & Small Investment Capital Gains - earlytimes.in
Ernexa Therapeutics (NASDAQ:ERNA) versus Savara (NASDAQ:SVRA) Critical Comparison - Defense World
Ernexa Therapeutics Inc. stock volume spike explained2025 Market Overview & Verified High Yield Trade Plans - newser.com
What analysts say about Ernexa Therapeutics Inc stockGrowth vs. Value Investing & Affordable Stock Market Tips - Early Times
Published on: 2025-09-22 07:32:05 - newser.com
Momentum divergence signals in Ernexa Therapeutics Inc. chartJuly 2025 Sentiment & Accurate Buy Signal Notifications - newser.com
Fund Flows: Will Ernexa Therapeutics Inc outperform tech stocksJuly 2025 PreEarnings & Risk Controlled Swing Alerts - خودرو بانک
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ernexa Therapeutics Inc Stock (ERNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% Owner |
Apr 02 '25 |
Buy |
0.10 |
3,768,397 |
394,174 |
20,401,602 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):